New ESR1 Biomarker Research Leads to FDA Approval for ER+, HER2- MBC with an ESR1 Mutation
At the end of January 2023, the FDA approved a new drug called elacestrant (OrserduTM) for people with estrogen receptor-positive, HER2-negative MBC with an ESR1...
Read More